TY - JOUR
T1 - BAL cytokine profile in different interstitial lung diseases
T2 - A focus on systemic sclerosis
AU - Meloni, Federica
AU - Caporali, Roberto
AU - Bianco, Alessia Marone
AU - Paschetto, Enrica
AU - Morosini, Monica
AU - Fietta, Anna Maria
AU - Patrizio, Vitulo
AU - Bobbio-Pallavicini, Francesca
AU - Pozzi, Ernesto
AU - Montecucco, Carlomaurizio
PY - 2004/6
Y1 - 2004/6
N2 - Background and aim: Fibrosing alveolitis develops in up to 80% of systemic sclerosis patients (SSc) but progression to end stage fibrosis occurs in about 15% of cases. Mechanisms leading to the process remain mostly unknown. We compared cytokine profiles of broncho-alveolar lavage fluids (BAL-f) from patients with SSc associated interstitial lung disease (SSc-ILD) (n. 34), idiopathic pulmonary fibrosis (IPF) (n. 13), stage II sarcoidosis (n. 14) and 9 controls. Methods: Interleukin (IL) 8, monocyte chemoattractant protein 1 (MCP-1), gamma-interferon (IFN-γ), IL 12, IL 18 and IL 10 and transforming growth factor-beta (TGF-β) were assessed by ELISA in concentrated BAL-f. Results: Levels of IL8 and MCP-1 were significantly elevated in SSc-ILD and in IPF as compared with controls (Mann Whitney test p <0.05), while MCP-1 values were significantly lower in SSc-ILD than in IPF. A significant correlation between neutrophils and IL8 levels (p = 0.047), as well as between eosinophils and MCP-1 levels (p = 0.004) was also observed. IFN-γ levels were slightly higher than normal only in sarcoidosis (p = 0.06), whereas IL12 levels increased both in sarcoidosis and SSc-ILD (p <0.05). No differences were found in IL18 and TGF-β levels. Finally, IL10 levels were higher in SSc-ILD and sarcoidosis than in controls and IPF (p <0.05). Conclusion: BAL-f cytokine profile differentiates ILD associated with SSc from IPF. The lower expression of MCP-1 and the higher expression of the anti-fibrotic IL12 and the anti-inflammatory IL10, observed both in sarcoidosis and in SSc-ILD, could account for the better prognosis of these ILDs. Further longitudinal studies are required to confirm whether a different cytokine phenotype may be considered predictive of clinical outcome in SSc-ILD.
AB - Background and aim: Fibrosing alveolitis develops in up to 80% of systemic sclerosis patients (SSc) but progression to end stage fibrosis occurs in about 15% of cases. Mechanisms leading to the process remain mostly unknown. We compared cytokine profiles of broncho-alveolar lavage fluids (BAL-f) from patients with SSc associated interstitial lung disease (SSc-ILD) (n. 34), idiopathic pulmonary fibrosis (IPF) (n. 13), stage II sarcoidosis (n. 14) and 9 controls. Methods: Interleukin (IL) 8, monocyte chemoattractant protein 1 (MCP-1), gamma-interferon (IFN-γ), IL 12, IL 18 and IL 10 and transforming growth factor-beta (TGF-β) were assessed by ELISA in concentrated BAL-f. Results: Levels of IL8 and MCP-1 were significantly elevated in SSc-ILD and in IPF as compared with controls (Mann Whitney test p <0.05), while MCP-1 values were significantly lower in SSc-ILD than in IPF. A significant correlation between neutrophils and IL8 levels (p = 0.047), as well as between eosinophils and MCP-1 levels (p = 0.004) was also observed. IFN-γ levels were slightly higher than normal only in sarcoidosis (p = 0.06), whereas IL12 levels increased both in sarcoidosis and SSc-ILD (p <0.05). No differences were found in IL18 and TGF-β levels. Finally, IL10 levels were higher in SSc-ILD and sarcoidosis than in controls and IPF (p <0.05). Conclusion: BAL-f cytokine profile differentiates ILD associated with SSc from IPF. The lower expression of MCP-1 and the higher expression of the anti-fibrotic IL12 and the anti-inflammatory IL10, observed both in sarcoidosis and in SSc-ILD, could account for the better prognosis of these ILDs. Further longitudinal studies are required to confirm whether a different cytokine phenotype may be considered predictive of clinical outcome in SSc-ILD.
KW - BAL-fluid
KW - Cytokines
KW - Idiopathic pulmonary fibrosis
KW - Interstitial lung disease
KW - Sarcoidosis
KW - Systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=3242667093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242667093&partnerID=8YFLogxK
M3 - Article
C2 - 15281432
AN - SCOPUS:3242667093
SN - 1124-0490
VL - 21
SP - 111
EP - 118
JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases
JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases
IS - 2
ER -